SCHEMBL3137401

SCHEMBL3137401

CCOC(=O)CN(CCNS(=O)(=O)c1nc2ccccc2s1)C(=O)Cn1cnc2c(NC(=O)OCc3ccc4c(c3)OCO4)ncnc21

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.34
LMNA P02545 3/20 0.34
KDM4E B2RXH2 2/20 0.34
POLB P06746 1/20 0.34
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
EDNRA P25101 1/20 0.33
ENPP2 Q13822 1/20 0.33
HTT P42858 1/20 0.32
PDE5A O76074 1/20 0.32
MAPT P10636 3/20 0.32
HPGD P15428 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TP53 P04637 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
GLO1 Q04760 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4844273 0.94 EDNRA (0.35) ALDH1A1LMNAKDM4EPOLBSMN1; SMN2
SCHEMBL3137591 0.90 KDR (0.38) ALDH1A1LMNAKDM4EPOLBSMN1; SMN2
SCHEMBL3136781 0.89 KDR (0.33) ALDH1A1POLBSMN1; SMN2MAPTHPGD
SCHEMBL3136494 0.89 SMN1; SMN2 (0.34) ALDH1A1LMNAKDM4EPOLBNOS1
SCHEMBL3132807 0.85 ABL1 (0.36) ALDH1A1LMNAKDM4EPOLBNOS1
SCHEMBL3253725 0.84 SMN1; SMN2 (0.33) ALDH1A1SMN1; SMN2MAPTMKNK1TDP1
SCHEMBL4838681 0.84 ABL1 (0.34) ALDH1A1LMNAKDM4EPOLBHTT
SCHEMBL4844303 0.84 MEN1 (0.35) ALDH1A1LMNAKDM4EPOLBSMN1; SMN2
SCHEMBL3136422 0.83 MAPK1 (0.32) KDM4ESMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4838731 0.83 PKM (0.34) ALDH1A1POLBSMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2174936-B1 PNA monomer and precursor PANAGENE INC (KR) 2013-09-04 EP disclosed
EP-2174936-A1 PNA monomer and precursor Panagene, Inc. (KR) 2010-04-14 EP disclosed
EP-1501812-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-12-30 EP disclosed
US-7411065-B2 Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids PANAGENE, INC. (KR) 2008-08-12 US disclosed
US-7371860-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2008-05-13 US disclosed
US-7371859-B2 Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields PANAGENE, INC. (KR) 2008-05-13 US disclosed
US-7179896-B2 Method of making PNA oligomers PANAGENE, INC. (KR) 2007-02-20 US disclosed
US-7145006-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2006-12-05 US disclosed
US-7125994-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2006-10-24 US disclosed
EP-1501812-A4 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2006-05-24 EP disclosed
US-20060030709-A1 Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields PANAGENE, INC. (KR) 2006-02-09 US disclosed
US-20060008835-A1 PNA monomer and precursor KIM SUNG K 2006-01-12 US disclosed
US-20060003374-A1 Method of making PNA oligomers KIM SUNG K 2006-01-05 US disclosed
US-20050283005-A1 PNA monomer and precursor KIM SUNG K 2005-12-22 US disclosed
US-6969766-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-29 US disclosed
US-20050250785-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-10 US disclosed
US-20050250786-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-10 US disclosed
EP-1501812-A1 PNA MONOMER AND PRECURSOR Panagene, Inc. (KR) 2005-02-02 EP disclosed
US-20030225252-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2003-12-04 US disclosed
WO-2003091231-A1 PNA MONOMER AND PRECURSOR PANAGENE, INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030709-A1 Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields RNGTT, POLL, RNMT ALDH1A1 3058/4885LMNA 975/4885KDM4E 4105/4885
US-20050283005-A1 PNA monomer and precursor PNISR, RNGTT, POLL ALDH1A1 3966/4885LMNA 683/4885KDM4E 4849/4885
US-20050250785-A1 PNA monomer and precursor PNISR, RNGTT, POLL ALDH1A1 3966/4885LMNA 683/4885KDM4E 4849/4885
US-20030225252-A1 PNA monomer and precursor PNISR, RNGTT, NCL ALDH1A1 4151/4885LMNA 720/4885KDM4E 4848/4885
US-20060008835-A1 PNA monomer and precursor PNISR, RNGTT, POLL ALDH1A1 3966/4885LMNA 683/4885KDM4E 4849/4885
US-20050250786-A1 PNA monomer and precursor PNISR, RNGTT, NPR1 ALDH1A1 3448/4885LMNA 553/4885KDM4E 4843/4885
US-20060003374-A1 Method of making PNA oligomers RNGTT, POLL, PNISR ALDH1A1 4029/4885LMNA 771/4885KDM4E 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.